Spain - Pharmaceuticals
For more information and to make a bid you will need to go to the third party website.
Details
Provided by
- Opportunity closing date
- 10 August 2020
- Opportunity publication date
- 08 July 2020
- Category
- 33600000: Ph
- Value of contract
- £5m-50m
- Your guide to exporting
Description
Framework agreement with a single company for the supply of the following pharmaceutical products: rituximab 500 mg/injectable IV; trastuzumab 150 mg/injectable; adalimumab 40 mg/parenteral; infliximab 100 mg/parenteral; etanercept 50 mg and 25 mg parenteral, for all the centers belonging to the Health Logistics Platform of Seville.
- Framework agreement with a single company for the supply of pharmaceutical products: rituximab 500 mg/injectable IV; trastuzumab 150 mg/injectable; adalimumab 40 mg/parenteral; infliximab 100 mg/parenteral; etanercept 50 mg and 25 mg parenteral, for all the centres attached to the Health Logistics Platform of Seville (CCA. 646X5BD),- total budget: 11 877 335.00 EUR (VAT included).
- Opportunity closing date
- 10 August 2020
- Value of contract
- £5m-50m
About the buyer
- Address
- Servicio Andaluz de Salud, Área Hospitalaria Virgen del Rocío Avenida Manuel Siurot, s/n Sevilla 41013 Spain
- Contact
- virginia.mora.sspa@juntadeandalucia.es
The deadline to apply for this opportunity has passed.
Visit the
opportunities page
to find another.